The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2021 | KEYNOTE-811: trastuzumab + chemotherapy with or without pembrolizumab for HER2+ G/GEJ cancer
Combination therapy with the anti-HER2 antibody trastuzumab with pembrolizumab and chemotherapy is the current standard of care for patients with HER2-positive metastatic gastric or gastroesophageal junction cancer (G/GEJ). In this interview, Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents the initial results from KEYNOTE-811 (NCT03615326), a Phase III study evaluating trastuzumab and chemotherapy with or without pembrolizumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.
